Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure.

American journal of cardiovascular drugs : drugs, devices, and other interventions - 1 Mar 2021

Alkhatib Nimer, Sweitzer Nancy K, Lee Christopher S, Erstad Brian, Slack Marion, Gharaibeh Mahdi, Karnes Jason, Klimecki Walter, Ramos Kenneth, Abraham Ivo

Abstract excerpt

OBJECTIVE: The Beta-Blocker Evaluation Survival Trial showed no survival benefit for bucindolol in New York Heart Association (NYHA) class III/IV heart failure (HF) with reduced ejection fraction, but subanalyses suggested survival benefits for non-Black subjects and Arg389 homozygotes. We conducted an ex ante economic evaluation of Arg389 targeted treatment with bucindolol versus carvidolol, complementing a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antihypertensive Agents
Share to Decision Trees

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hospitalization

Share to Patient Acceptance of Health Care

Share to Propanolamines

Share to Quality-Adjusted Life Years

Share to Receptors, Adrenergic, beta-1

Share to Stroke Volume

Source

Identifiers

PMID: 32710439
DOI: 10.1007/s40256-020-00425-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure.PMID 32710439Read ↗

Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure.Semantic proximity Read ↗

Combinatorial Pharmacogenetic Interactions of Bucindolol and β1, α2C Adrenergic Receptor PolymorphismsSemantic proximity Read ↗

Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation.Semantic proximity Read ↗

A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure.Semantic proximity Read ↗

Cost effectiveness of targeted high-dose atorvastatin therapy following genotype testing in patients with acute coronary syndrome.Semantic proximity Read ↗

Economic evaluation of Cardio inCode®, a clinical-genetic function for coronary heart disease risk assessment.Semantic proximity Read ↗

A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial.Semantic proximity Read ↗

Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure.Semantic proximity Read ↗

The Cost-Effectiveness of B-type Natriuretic Peptide-Guided Care in Compared to Standard Clinical Assessment in Outpatients With Heart Failure in Tehran, IranSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.